首页|Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
Immune checkpoint blockade(ICB)therapy is a powerful option for cancer treatment.Despite demonstrable progress,most patients fail to respond or achieve durable responses due to primary or acquired ICB resistance.Recently,tumor epithelial-to-mesenchymal plasticity(EMP)was identified as a critical determinant in regulating immune escape and immunotherapy resistance in cancer.In this review,we summarize the emerging role of tumor EMP in ICB resistance and the tumor-intrinsic or extrinsic mechanisms by which tumors exploit EMP to achieve immunosuppression and immune escape.We discuss strategies to modulate tumor EMP to alleviate immune resistance and to enhance the efficiency of ICB therapy.Our discussion provides new prospects to enhance the ICB response for therapeutic gain in cancer patients.
万方数据
